Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells
The beta-glucocerebrosidase (GBA1) gene encodes the lysosomal beta-glucocerebrosidase (GCase) that metabolizes the lipids glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph). Biallelic loss-of-function mutations in GBA1 such as L444P cause Gaucher disease (GD), which is the most prevalent lys...
Main Authors: | Yusuke Naito, Sou Sakamoto, Takuto Kojima, Misaki Homma, Maiko Tanaka, Hideki Matsui |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | SLAS Discovery |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2472555223000485 |
Similar Items
-
Consequences of excessive glucosylsphingosine in glucocerebrosidase-deficient zebrafish.
by: Lindsey T. Lelieveld, et al.
Published: (2022-05-01) -
Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism
by: Benjamin McMahon, et al.
Published: (2016-01-01) -
Ex vivo generation of platelet products from human iPS cells
by: Sou Nakamura, et al.
Published: (2020-12-01) -
Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease.
by: Trapero, A, et al.
Published: (2012) -
Galactosyl- and glucosylsphingosine induce lysosomal membrane permeabilization and cell death in cancer cells.
by: Kamilla Stahl-Meyer, et al.
Published: (2022-01-01)